Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Tenaya Therapeutics, Inc.TNYA · Entity 6506 | Director | May 28, 2026 | May 29, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Tenaya Therapeutics, Inc.
Report date May 28, 2026 · Filed May 29, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.80 · Expires 2036-05-27 | Direct | 120,000 |
Reported balance
After 2026-05-28 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-05-28 · Grant · Acquired 120,000 · Balance 120,000 F1: Option granted pursuant to the Amended and Restated Tenaya Therapeutics, Inc. 2021 Equity Incentive Plan. Option will vest in full May 28, 2027, or, if earlier, the day immediately before the date of the next annual meeting of stockholders that occurs after the grant date, subject to the Reporting Person continuing to be a service provider to the Issuer through each applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Option granted pursuant to the Amended and Restated Tenaya Therapeutics, Inc. 2021 Equity Incentive Plan. Option will vest in full May 28, 2027, or, if earlier, the day immediately before the date of the next annual meeting of stockholders that occurs after the grant date, subject to the Reporting Person continuing to be a service provider to the Issuer through each applicable vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 28, 2026 Filed May 29, 2026 23:13 UTC | Tenaya Therapeutics, Inc. TNYA · Entity 6506 | GrantStock Option (Right to buy) · Derivative | 120,000 | $0.00 Strike: $0.80 | $0.00 |
DisclosureSEC source: 0001193125-26-249116 · ownership.xml · derivative · entry 1 Srivastava Deepak · CIK 0001868501 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 120,000 Underlying: Common Stock · 120,000 shares Expires 2036-05-27 F1 · derivative.exercise_date: Option granted pursuant to the Amended and Restated Tenaya Therapeutics, Inc. 2021 Equity Incentive Plan. Option will vest in full May 28, 2027, or, if earlier, the day immediately before the date of the next annual meeting of stockholders that occurs after the grant date, subject to the Reporting Person continuing to be a service provider to the Issuer through each applicable vesting date. Read SEC document |
| May 29, 2025 Filed May 30, 2025 22:50 UTC | Tenaya Therapeutics, Inc. TNYA · Entity 6506 | GrantStock Option (Right to buy) · Derivative | 107,400 | $0.00 Strike: $0.44 | $0.00 |
DisclosureSEC source: 0000950170-25-079944 · ownership.xml · derivative · entry 1 Srivastava Deepak · CIK 0001868501 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 107,400 Underlying: Common Stock · 107,400 shares Expires 2035-05-28 F1 · derivative.exercise_date: Option granted pursuant to the Tenaya Therapeutics, Inc. 2021 Equity Incentive Plan. Option will vest in full May 29, 2026, or, if earlier, the day immediately before the date of the next annual meeting of stockholders that occurs after the grant date, subject to the Reporting Person continuing to be a service provider to the Issuer through each applicable vesting date. Read SEC document |
| October 18, 2024 Filed Oct 22, 2024 00:40 UTC | Tenaya Therapeutics, Inc. TNYA · Entity 6506 | GrantStock Option (Right to buy) · Derivative | 34,000 | $0.00 Strike: $2.04 | $0.00 |
DisclosureSEC source: 0000950170-24-116062 · ownership.xml · derivative · entry 1 Srivastava Deepak · CIK 0001868501 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,000 Underlying: Common Stock · 34,000 shares Expires 2034-10-17 F1 · derivative.exercise_date: Option granted pursuant to the Tenaya Therapeutics, Inc. 2021 Equity Incentive Plan. Option will vest in full May 31, 2025, or, if earlier, the day immediately before the date of the next annual meeting of stockholders that occurs after the grant date, subject to the Reporting Person continuing to be a service provider to the Issuer through each applicable vesting date. Read SEC document |
| June 09, 2023 Filed Jun 13, 2023 00:30 UTC | Tenaya Therapeutics, Inc. TNYA · Entity 6506 | GrantStock Option (Right to buy) · Derivative | 29,532 | $0.00 Strike: $7.12 | $0.00 |
DisclosureSEC source: 0001209191-23-036514 · doc4.xml · derivative · entry 1 Srivastava Deepak · CIK 0001868501 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,532 Underlying: Common Stock · 29,532 shares Expires 2033-06-08 F1 · derivative.exercise_date: Option granted pursuant to the Tenaya Therapeutics, Inc. 2021 Equity Incentive Plan. Option will vest in full upon the first anniversary of the date of grant or, if earlier, the day immediately before the date of the next annual meeting of stockholders that occurs after the grant date, subject to the Reporting Person continuing to be a service provider to the Issuer through each applicable vesting date. Read SEC document |
| November 21, 2022 Filed Dec 10, 2022 00:59 UTC | Tenaya Therapeutics, Inc. TNYA · Entity 6506 | PurchaseCommon Stock | 230,769 | $2.60 | $599,999.40 |
DisclosureSEC source: 0001209191-22-060596 · doc4.xml · nonDerivative · entry 1 Srivastava Deepak · CIK 0001868501 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 372,435 F1 · ownership.nature: These shares are held directly by The J. David Gladstone Institutes for which the Reporting Person serves as President. The Reporting Person may be deemed to have voting and investment control over the shares. The Reporting Person disclaims beneficial ownership of these shares. This report shall not be deemed an admission that the Reporting Person is the beneficial owner of any of the shares held by The J. David Gladstone Institutes for Section 16 or any other purpose. Read SEC document |
| June 10, 2022 Filed Jun 14, 2022 00:58 UTC | Tenaya Therapeutics, Inc. TNYA · Entity 6506 | GrantStock Option (Right to buy) · Derivative | 39,727 | $0.00 Strike: $5.26 | $0.00 |
DisclosureSEC source: 0001209191-22-036534 · doc4.xml · derivative · entry 1 Srivastava Deepak · CIK 0001868501 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,727 Underlying: Common Stock · 39,727 shares Expires 2032-06-09 F1 · derivative.exercise_date: Option granted pursuant to the Tenaya Therapeutics, Inc. 2021 Equity Incentive Plan. Option will vest in full upon the first anniversary of the date of grant or, if earlier, the day immediately before the date of the next annual meeting of stockholders that occurs after the grant date, subject to the Reporting Person continuing to be a service provider to the Issuer through each applicable vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.